Dirucotide

Dirucotide is a synthetic peptide that is being studied for its potential use in the treatment of Multiple Sclerosis (MS). It is designed to target the myelin basic protein (MBP), a component of the myelin sheath that insulates nerve fibers in the brain and spinal cord.

Mechanism of Action[edit | edit source]

Dirucotide's mechanism of action is believed to involve the modulation of the immune response to MBP. In MS, the immune system mistakenly attacks the myelin sheath, leading to nerve damage and the symptoms of the disease. By binding to MBP, Dirucotide may help to redirect the immune response away from the myelin sheath.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to evaluate the safety and efficacy of Dirucotide in patients with MS. These include the MAESTRO-01, MAESTRO-02, and MAESTRO-03 trials. While some trials have shown promising results, others have failed to meet their primary endpoints, and the overall clinical benefit of Dirucotide remains uncertain.

Development and Regulatory Status[edit | edit source]

Dirucotide was developed by BioMS Medical, a Canadian biotechnology company. In 2009, the company entered into a licensing agreement with Eli Lilly and Company for the global rights to the drug. However, following disappointing results from the MAESTRO-03 trial, Eli Lilly terminated the agreement in 2010. As of 2021, the development and regulatory status of Dirucotide is unclear.